The Online Investor
Mallinckrodt Plc (MNK)

Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.
Company Name: 
Mallinckrodt Plc
Stock buyback: 
MNK buyback
Website: 
www.mallinckrodt.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree MNK Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Sell (1.12 out of 4)
51st percentile
(ranked higher than approx. 51% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mallinckrodt Plc (MNK) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.